ACP-DA: Improving the Prediction of Anticancer Peptides Using Data Augmentation

Xian-gan Chen1,2,3, Wen Zhang4,5,*, Xiaofei Yang1,2,3, Chenhong Li1,2,3 and Hengling Chen1,2,3

1 School of Biomedical Engineering, South-Central University for Nationalities, Wuhan, China, 2 Hubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, South-Central University for Nationalities, Wuhan, China, 3 Key Laboratory of Cognitive Science (South-Central University for Nationalities), State Ethnic Affairs Commission, Wuhan, China, 4 College of Informatics, Huazhong Agricultural University, Wuhan, China, 5 Hubei Engineering Technology Research Center of Agricultural Big Data, Wuhan, China

Anticancer peptides (ACPs) have provided a promising perspective for cancer treatment, and the prediction of ACPs is very important for the discovery of new cancer treatment drugs. It is time consuming and expensive to use experimental methods to identify ACPs, so computational methods for ACP identification are urgently needed. There have been many effective computational methods, especially machine learning-based methods, proposed for such predictions. Most of the current machine learning methods try to find suitable features or design effective feature learning techniques to accurately represent ACPs. However, the performance of these methods can be further improved for cases with insufficient numbers of samples. In this article, we propose an ACP prediction model called ACP-DA (Data Augmentation), which uses data augmentation for insufficient samples to improve the prediction performance. In our method, to better exploit the information of peptide sequences, peptide sequences are represented by integrating binary profile features and AAindex features, and then the samples in the training set are augmented in the feature space. After data augmentation, the samples are used to train the machine learning model, which is used to predict ACPs. The performance of ACP-DA exceeds that of existing methods, and ACP-DA achieves better performance in the prediction of ACPs compared with a method without data augmentation. The proposed method is available at http://github.com/chenxgscuec/ACPDA.

Keywords: anticancer peptide prediction, data augmentation, feature representation, multilayer perception, machine learning

INTRODUCTION

With the increase in population age, cancer has become one of the most threatening diseases for humans (Bray et al., 2018; Zhang et al., 2020). The complexity and heterogeneity of cancer make it difficult to treat. Traditional clinical methods such as surgery, radiotherapy, and chemotherapy can be used to treat cancer, but the side effects of these methods are very obvious and can cause great discomfort for patients (Doja et al., 2020). Although traditional anticancer drugs are effective,
their shortcomings, such as gastrointestinal damage (Mitchell, 2006), are also notable and can easily cause multidrug tumor resistance (Holohan et al., 2013; Wijdeven et al., 2016). In view of these problems, it is urgent to find and design novel cancer treatments and anticancer agents to fight cancer. In recent years, due to their high specificity, low production cost, and low toxicity profile, peptides have emerged as alternative anticancer agents (Otvos, 2008).

Anticancer peptides (ACPs), a class of naturally occurring important defense substances, provide a new direction for research involving novel anticancer drugs. ACPs are usually short peptides with a length of 10–50 amino acids. Since ACPs only interact with the anionic cell membrane components of cancer cells, they exhibit extensive cytotoxicity against a variety of cancer cells but not normal cells (Barras and Widmann, 2011; Boohaker et al., 2012). There are currently many peptide-based therapies being evaluated for their efficacy in treating tumors. However, only a few peptides can be used for clinical treatment. Therefore, the discovery of new ACPs is of great significance to the successful clinical application of these peptides. An increasing number of ACPs from protein sequences have been identified and verified by experiments (Tyagi et al., 2013), but it is time consuming and expensive to use experimental methods to identify ACPs. Therefore, computational methods for ACP identification are urgently needed.

There are many computational methods in the field of bioinformatics, that are used to solve different kinds of bioinformatics problems (Zou et al., 2018; Zou, 2019; Deng et al., 2020; Huang et al., 2020). There are many computational methods, especially machine learning-based methods, for the identification of ACPs. Anti-CP was the first computational tool based on a support vector machine (SVM), which used sequence-based features and binary profiles (Tyagi et al., 2013). Hajisharifi et al. (2014) considered Chou’s pseudo amino acid composition (PseAAC) and local alignment kernel for the prediction of ACPs (Amanat et al., 2020; Hasan et al., 2020; Naseer et al., 2020). Chen et al. (2016) developed a method based on the optimization of g-gap dipeptide components. Li and Wang (2016) selected the amino acid composition, average chemical shifts, and reduced amino acid composition to represent ACPs. Wei et al. (2018) developed a feature representation learning model with a two-step feature selection technique to improve the prediction of ACPs. Xu et al. (2018) proposed using 400-dimensional features with g-gap dipeptide features for ACPs. Boopathi et al. (2019) applied a two-step method to obtain optimal feature vectors, which were used as inputs for a SVM. Ge et al. (2019) proposed a generalized chaos game representation (CGR) for ACP identification. Ge et al. (2020) used different features and multiple classifiers and the classifier outputs were used as inputs for a SVM, which was used to identify ACPs. Yu et al. (2020) explored three different deep learning architectures and found that recurrent neural networks are superior to other architectures. Zhao et al. (2020) used a deep belief network to encode the sequences and chemical features of ACPs and applied random relevance vector machines to identify ACPs. Yi et al., 2019 proposed a deep learning long short-term memory (LSTM) neural network model called ACP-DL to predict novel ACPs. Agrawal et al., 2020 used various features and different machine learning classifiers on two datasets for the prediction of ACPs.

However, the number of ACPs involved in the above methods did not exceed 1000 cases, which is not a large number. The performance of these methods could potentially be further improved if additional ACPs are considered. In this article, we use data augmentation to increase the number of samples in the training set and further improve the performance of ACP prediction methods based on machine learning. Specifically, we propose an ACP prediction model with Data Augmentation, named ACP-DA. In our method, binary profile features (BPFs) and the features that describe the physicochemical properties of amino acids are concatenated to represent peptides, and the samples in the training set are augmented in the feature space. The samples after data augmentation are used to train a machine learning model, which is used for the prediction of ACPs.

The flowchart of ACP-DA is shown in Figure 1. There are four major steps in our method. First, given peptide sequences as the input, each sequence is preprocessed to equal length. Second, the peptide sequences are represented by concatenating BPFs and AAindex features selected based on minimum redundancy maximum relevance (mRMR). Third, data augmentation is performed in the feature space of samples in the training set. Ultimately, the data-augmented samples are used to train a multilayer perceptron (MLP) model, and the trained MLP model assigns labels to the samples in the testing set. To evaluate the performance of our method, we used five-fold cross-validation to evaluate ACP-DA based on two benchmark datasets: ACP740 and ACP240. We discuss the performance of this method with different parameters and evaluate the effect of data augmentation based on different classifiers. The experimental results show that data augmentation can help improve the prediction of ACPs under the condition of using suitable classifiers, and our method is suitable for ACP prediction.

MATERIALS AND METHODS

Datasets

A good dataset is very important for establishing a reliable ACP prediction model. In recent years, several excellent datasets have been established (Wei et al., 2018; Yi et al., 2019). We selected two benchmark datasets, ACP740 and ACP240, which have more samples (Yi et al., 2019) than others. The similarities between the two datasets were as follow: ACPs verified in the experiment were regarded as positive samples, and anti-microbial peptides (AMPs) without anticancer function were regarded as negative samples. CD-HIT was used to remove the peptide sequences with a similarity of more than 90%. The difference was that ACP740 was from Chen et al.’s and Wei et al.’s studies, while ACP240 was from Yi et al.’s studies. There were 376 positive samples and 364 negative samples in ACP740, and there were 129 positive samples and 111 negative samples in ACP240. There were no overlapping data between ACP740 and ACP240, and both are non-redundant datasets. These two datasets are available at https://github.com/haichengyi/ACP-DL.
FIGURE 1 | Flowchart of ACP-DA. Binary profile features (BPFs) and AAindex features after feature selection were concatenated to represent peptides, and the samples in the training set were augmented in the feature space. The samples after data augmentation were used to train the multilayer perception (MLP) model, which was used for the prediction of anticancer peptides (ACPs).

**Prediction Framework**

To identify potential ACPs, we propose an ACP prediction model called ACP-DA. **Figure 1** illustrates the framework of the proposed method. First, we preprocess the peptide sequences to equal length, and the length is selected to be \( L_X \) amino acids so that the next feature calculation can be performed. Second, the AAindex in the iFeature Python package (Chen et al., 2018) is used to calculate the physicochemical properties of the amino acids in each sequence, and mRMR (Peng et al., 2005) is then used for feature selection. BPFs and AAindex features after feature selection for each peptide sequence are concatenated to represent a peptide. Third, data augmentation is performed in the feature space of samples in the training set for subsequent processing. Finally, the data-augmented samples are used to train the MLP model; the trained MLP model assigns labels to the samples in the testing set. The following sections describe the steps in our framework in detail.

**Preprocessing**

Since the AAindex in the iFeature Python package can only encode peptides of the same length, we need to preprocess the original peptide sequences to obtain peptides of the same lengths. To obtain the best sequence length, we need to know the length distribution of all samples. We performed statistical analyses of the length of the peptides in the ACP740 and ACP240 datasets. As shown in **Figure 2**, most of the peptides were less than 60 amino acids in length. To obtain peptides of the same length, we processed each peptide as follows. For sequences less than \( L_X \) amino acids, each peptide was padded with “X” until \( L_X \) amino acids were reached. For sequences greater than \( L_X \) amino acids, the extra amino acids after \( L_X \) were removed, and only the first \( L_X \) amino acids were reserved. \( L_X \) can be selected as 40, 50, or 60. We think the best length can be derived from the three numbers.

**FIGURE 2 | Sequence length statistics for all peptides in the ACP740 and ACP240 dataset.**
Representation of Peptides

The main objective of feature representation is to convert peptides of different lengths into fixed-length feature vectors (Zhang and Liu, 2019). The unprocessed peptide sequence $P$ can be represented as:

$$P = p_1p_2...p_L$$

where $p_1$ is the first residue of $P$ and $p_L$ is the last residue of $P$. $L$ is the length of $P$. $p_i$ ($1 \leq i \leq L$) is an element of the standard amino acid alphabet $\{A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y\}$. After preprocessing, the peptide sequence can be expressed as:

$$P = p_1p_2...p_{LX}$$

Different feature representation methods describe different properties of peptide sequences. If two features have complementary characteristics, combining the two features will help to improve the performance of the predictive model. However, more features don’t necessarily lead to better performance. Too many features may cause redundancy, resulting in performance degradation. So, we tested three feature representation methods and their concatenations: BPFs, AAindex, and K-mer sparse matrix.

Binary Profile Features

There are 20 different amino acids in the standard amino acid alphabet. In BPFs, each amino acid is encoded by a feature vector composed of zeroes and ones. The first amino acid type $A$ in the above amino acid alphabet is encoded as $f(A) = (1, 0, ..., 0)$, the second amino acid type $C$ is encoded as $f(C) = (0, 1, ..., 0)$, and so on. For each given peptide, the N-terminus of $k$ amino acids is encoded as the following feature vector:

$$F_{BPF} = [f(p_1), f(p_2), ..., f(p_k)]$$

Experiments derived from ACP-DL (Yi et al., 2019) show that the result is best when $k$ is 7, which means that only the first 7 amino acids in each peptide sequence are encoded; therefore, the dimension of $F_{BPF}$ is $20 \times 7 = 140$.

AAindex

The physicochemical properties of amino acids represent the characteristics of biochemical reactions and have been widely used in bioinformatics research. The AAindex is a database of amino acid indices representing the physicochemical and biochemical properties of amino acids (Kawashima et al., 2008). We used the AAindex in the iFeature Python package to represent peptides. The AAIndex descriptor can only be used to encode peptides of equal length (Tung and Ho, 2008). The preprocessing steps in the previous section changed peptides of different lengths to peptides of equal length for encoding based on the AAindex. If $L_k$ in the above section is set to 40, the AAindex descriptor calculated for a peptide of 40 amino acids will result in a 21,240-dimensional feature vector. The dimension of the features is too large, which may cause dimension disaster. mRMR is an excellent dimension reduction technology, and it has good application properties in many scenarios. Therefore, we selected the 50 most informative candidate features by using mRMR for more efficiency.

K-mer Sparse Matrix

K-mer of peptides is composed of $K$ amino acids. Suppose the length of a peptide sequence is $L$, there will be $7^K$ different possible K-mer and an $L − K + 1$ step appearing in the sequence. One peptide sequence is transformed to a $7^K \times (L − K + 1)$ K-mer sparse matrix $M$, which is a low-rank matrix. Singular value decomposition (SVD) is used to convert this matrix into a 343-dimension feature vector.

A new feature vector is formed to represent peptides by concatenating the above feature representations of each peptide. If BPFs and AAindex are selected, the dimension of the new feature vector is $140 + 50 = 190$.

Data Augmentation

When using machine learning technology to solve scientific problems, insufficient data (Han et al., 2020) or data imbalance (Fu et al., 2020; Gao et al., 2020; Mahmud et al., 2021) issues are common. Collecting more data can certainly solve these problems, but sometimes it may be difficult to obtain more data due to cost restrictions or other reasons. In such cases, data augmentation can potentially be efficient. Data augmentation has mainly historically been used in the field of computer vision (Chaitanya et al., 2021; Wang et al., 2021), and novel samples can be obtained by flipping, rotating, scaling, and cropping the original samples in the methods of data augmentation. In the field of bioinformatics, there will sometimes be data imbalances (Zou et al., 2016; Wan et al., 2017; Meng et al., 2019). Data augmentation can be used to solve data imbalance problems (Chen et al., 2020). Here, we are facing the insufficient sample problem, which can be solved by data augmentation. Four oversampling techniques are used to generate new samples in feature space to improve the performance of the RNA coding potential prediction model (Chen et al., 2020). Noise adding oversampling (NAO) is the best. We also use this technique to generate new samples.

To improve the performance of the ACP prediction model, we augmented the positive and negative samples in the datasets, respectively. Data augmentation is achieved by adding perturbation values to the original samples in the feature space to generate pseudosamples. The features of a peptide include two parts: BPFs and the AAindex. BPFs are binary codes composed of 0 and 1, which are not suitable for adding perturbations. So, we only add perturbations to the AAindex, and the BPFs remain unchanged. A new sample $F_{new}$ is generated by the following mathematical formula:

$$F_{new} = F_i \ast V \ast a + F_i$$

where $F_i$ is a random sample from the training samples of peptide sequences and $i = 1, ..., N$. $N$ is the total number of positive (negative) samples. $V$ is a 190-dimensional vector for generating perturbations that corresponds to $F_i$. Because perturbations are not added to BPFs, $V$ is composed of two parts: one is a 140-dimensional vector of zeros corresponding to BPFs, and the other is a 50-dimensional random vector with values between 0 and 1 corresponding to AAindex. Thus, perturbations are added to AAindex features, and BPFs are kept unchanged in the
pseudosample set $F_{\text{new}}$. $\alpha$ is the coefficient of the perturbation and is set to 0.005 for the ACP740 dataset. We repeat the sampling process $N$ times to obtain $N$ new samples.

**Classifier**
The MLP classifier is an artificial neural network composed of an input layer, a hidden layer, and an output layer. The hidden layer can be a single layer or multiple layers, and the layers are fully connected. A back propagation (BP) algorithm is used to train the MLP classifier (Rumelhart et al., 1986). Due to its excellent classification performance, this classifier has been used in many fields of bioinformatics, as noted in Auer et al. (2020). For implementation, we used the scikit-learn Python package; the hidden layer was composed of 6 sublayers, each with 100 neurons. The $L_2$ penalty (regularization term) parameter was 0.01, and the other parameters were set to default values. We employed the MLP classifier to train our predictive model. In this work, we also tested other classifiers, including SVM (Fan et al., 2008), random forest (RF) (Breiman, 2001), MLP, decision tree (DT), and extremely randomized trees (ExtraTrees) (Geurts et al., 2006) classifiers, to build prediction models based on the augmented data in the training set. Among these classifiers, the MLP classifier works best according to the experiments section.

**Performance Evaluation**
We used five-fold cross-validation to evaluate the performance of ACP-DA. In the evaluation, five metrics were used in the binary classification tasks. The five metrics were accuracy (ACC), precision (PRE), sensitivity (SN), specificity (SP), and the Matthews correlation coefficient (MCC), which were widely used in bioinformatics (Zhang et al., 2019). These metrics are defined as follows:

$$ACC = \frac{TP + TN}{TP + TN + FP + FN}$$

$$PRE = \frac{TP}{TP + FP}$$

$$SN = \frac{TP}{TP + FN}$$

$$SP = \frac{TN}{TN + FP}$$

$$MCC = \frac{TP*TN-FP*FN}{\sqrt{(TP + FN)*(TP + FP)*(TN + FP)*(TN + FN)}}$$

where TP stands for true positives and FN, TN, and FP stand for false negatives, true negatives, and false positives, respectively. MCC is a comprehensive performance evaluation metric.

**RESULTS**
In this section, we first discuss the effects of two important parameters on the performance of our method and then compare the performance of the model for different features. We also analyze the effect of data augmentation in the case of using different classifiers. Finally, we compare our method with existing methods.

**Parameter Discussion**
Two parameters affect the performance of the model. One is $L_X$ in the preprocessing step, which is the length of the peptide sequence after preprocessing. $L_X$ can be set to 40, 50, or 60. The other parameter is $N$, which is related to the number of new positive (negative) samples in the data augmentation step. Here, we use the training samples after data augmentation to build the prediction model with 100, 200, or 300% of the original positive (negative) sample number as new samples. Thus, $N$ may be set to 100, 200, or 300% of the original positive (negative) sample number.

For the ACP740 and ACP240 datasets, the performance of the prediction models established based on different parameters is shown in Tables 1, 2. MCC is a comprehensive performance evaluation metric, and larger MCC values mean better performance. Therefore, we choose the best parameters $L_X$ 40 and $N$ 100% for ACP740 and $L_X$ 40 and $N$ 300% for ACP240 according to the maximum MCC value. The N value of ACP240 is larger than that of ACP740, which means that more pseudosamples are needed for ACP240 than ACP740 because ACP240 has fewer samples than ACP740.

**Comparisons With Different Features**
Binary profile feature and k-mer sparse matrix have been proved to be effective in ACP-DL (Yi et al., 2019), and AAindex has also been mentioned in physicochemical property based therapeutic

**TABLE 1** | Performance of ACP-DA with different parameters based on ACP740 (The best metrics are in bold).

| $L_X$ | $N$ | ACC (%) | PRE (%) | SE (%) | SP (%) | MCC (%) |
|-------|-----|---------|---------|--------|--------|---------|
| 40    | 100% | 81.89   | 84.14   | 80.59  | 83.23  | 64.71   |
| 40    | 200% | 82.02   | 83.46   | 80.89  | 82.26  | 64.56   |
| 40    | 300% | 81.49   | 82.89   | 80.88  | 82.15  | 63.40   |
| 50    | 100% | 80.41   | 83.35   | 79.02  | 81.88  | 62.59   |
| 50    | 200% | 82.03   | 81.51   | 84.57  | 79.36  | 64.68   |
| 50    | 300% | 80.27   | 77.23   | 86.98  | 73.35  | 61.17   |
| 60    | 100% | 79.19   | 80.18   | 79.54  | 78.85  | 58.89   |
| 60    | 200% | 78.37   | 77.72   | 81.67  | 75.01  | 57.21   |
| 60    | 300% | 79.73   | 79.14   | 81.93  | 77.47  | 59.61   |

**TABLE 2** | Performance of ACP-DA with different parameters based on ACP240 (The best metrics are in bold).

| $L_X$ | $N$ | ACC (%) | PRE (%) | SE (%) | SP (%) | MCC (%) |
|-------|-----|---------|---------|--------|--------|---------|
| 40    | 100% | 85.42   | 83.43   | 92.28  | 77.59  | 71.57   |
| 40    | 200% | 87.92   | 87.17   | 91.48  | 83.91  | 76.03   |
| 40    | 300% | 88.33   | 90.11   | 88.37  | 88.30  | 76.68   |
| 50    | 100% | 85.00   | 84.71   | 88.43  | 81.11  | 70.10   |
| 50    | 200% | 83.75   | 84.80   | 86.12  | 81.10  | 68.10   |
| 50    | 300% | 85.42   | 86.48   | 86.86  | 83.83  | 71.03   |
| 60    | 100% | 86.25   | 84.35   | 92.28  | 79.37  | 72.97   |
| 60    | 200% | 87.08   | 86.89   | 90.74  | 83.04  | 74.64   |
| 60    | 300% | 87.92   | 85.70   | 93.78  | 81.11  | 76.26   |
As a complex disease, cancer involves complex biological processes. The complex mechanisms of cancer make it difficult to trace the cause. Despite the emergence of various cancer treatment strategies, most of the strategies have been unsatisfactory. Due to its high specificity, high tissue penetration, low production cost and other advantages, treatment based on ACPs has become a potential cancer treatment method. Most ACPs come from protein sequences. The development of high-throughput sequencing technology has brought an increase in the number of available proteins, and it is expected that the number of ACPs will also increase. It is time-consuming and expensive to use experimental methods to discover ACPs from protein sequence data. Therefore, it is urgent to develop computational methods to speed up the identification of ACPs.
In this paper, an ACP prediction method called ACP-DA is proposed. According to the results on the two datasets of ACP740 and ACP240, our model has good overall performance. Compared with existing methods, our method has a better effect in identifying whether the peptide sequence is ACP, and its accuracy may be attributed to the following reasons.

First, how to use effective feature representation methods to characterize peptide sequences is a major challenge in current prediction methods. To find an effective feature or feature combination, we tested 3 feature representation methods and their feature combinations: BPF, AAindex, k-mer, BPF + AAindex, BPF + k-mer, AAindex + k-mer, BPF + AAindex + k-mer. Experiments on the ACP740 and ACP240 datasets show that BPF + AAindex obtains the best performance, so we use BPF + AAindex to represent the peptide sequences.

Second, we used data augmentation to increase the samples in the training set for the insufficient samples. Data augmentation is achieved by generating pseudosamples based on the original samples. The specific method of generating pseudosamples is to add disturbances in the feature space of the original sample. The feature space of the sample is formed by the concatenation of BPF and AAindex. BPF is a code composed of 0 and 1, which is not suitable for adding disturbance, so, we only add disturbance on AAindex to generate pseudosamples. The model is trained with the augmented data to further improve the performance of the prediction model.

Finally, various classifiers show good performance in many classification tasks of bioinformatics. However, it is still unknown whether our data augmentation method can improve the performance of prediction models under various types of classifiers. Therefore, we tested the effect of this method in the case of using five different classifiers. The results show that data augmentation is effective when using MLP, SVM, and ExtraTrees, and data augmentation may not be effective when using RF or DT. Therefore, we choose the MLP with the best overall performance as the final classifier.

The main innovation of this article lies in the use of data augmentation methods. From the experimental results, the method is of great significance. When using MLP, SVM, and ExtraTrees as classifiers, the use of data augmentation can significantly improve the performance of the prediction model. Moreover, a comparative analysis with other methods shows that ACP-DA is better than other methods in most cases.

In short, we provide a new idea for the identification of ACPs, and hope that ACP-DA will play an important role in the development of new anticancer drugs.
CONCLUSION

In this work, we proposed a novel ACP prediction model called ACP-DA. To establish an effective prediction model, we concatenated BPfs and the AAIxIndex to represent peptide sequences. We performed data augmentation in the feature space and used the augmented data to train the prediction model. The experimental results show that the proposed method can effectively distinguish ACPs and non-ACP. Compared with the method without data augmentation, ACP-DA achieves better performance. ACP-DA will be a useful tool for the discovery of novel potential ACPs.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://github.com/haichengyi/ACP-DL.

REFERENCES

Agrawal, P., Bhagat, D., Mahalwal, M., Sharma, N., and Raghava, G. P. S. (2020). AnticP 2.0: an updated model for predicting anticancer peptides. Brief Bioinform. 22:bbaa153. doi: 10.1093/bib/bbaa153
Amanat, S., Ashraf, A., Hussain, W., Rasool, N., and Khan, Y. D. (2020). Identification of lysine carboxylation sites in proteins by integrating statistical moments and position relative features via general PseAAC. Curr. Bioinform. 15, 396–407. doi: 10.2174/157489361466619072314923
Auer, A., Strauss, M. T., Strauss, S., and Jungmann, R. (2020). nanoTRON: a Picasso module for MLP-based classification of super-resolution data. Bioinformatics 36, 3620–3622. doi: 10.1093/bioinformatics/btaa154
Barras, D., and Widmann, C. (2011). Promises of apoptosis-inducing peptides in cancer therapeutics. Curr. Pharm. Biotechnol. 12, 1153–1165. doi: 10.2174/1389201111796174737
Boohaker, R. J., Lee, M. W., Vishnubhotla, P., Perez, J. M., and Khaled, A. R. (2012). The use of therapeutic peptides to target and to kill cancer cells. Curr. Med. Chem. 19, 3794–3804. doi: 10.2174/0929867128016610041
Boopathi, V., Subramaniyam, S., Malik, A., Lee, G., Manavalan, B., and Yang, D. C. (2019). mAACPred: a support vector machine-based meta-predictor for identification of anticancer peptides. Int. J. Mol. Sci. 20:1964. doi: 10.3390/ijms20081964
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. doi: 10.3322/caac.21492
Breiman, L. (2001). Random forests. Machine Learn. 45, 5–32.
Chaitanya, K., Karani, N., Baumgartner, C. F., Erdil, E., Becker, A., Donati, O., et al. (2021). Semi-supervised task-driven data augmentation for medical image segmentation. Med. Image Anal. 68:101934. doi: 10.1016/j.media.2020.101934
Chen, W., Ding, H., Feng, P., Lin, H., and Chou, K. C. (2016). iACP: a sequence-based tool for identifying anticancer peptides. Oncotarget 7, 16895–16909. doi: 10.18632/oncotarget.7815
Chen, G. C., Liu, S., and Zhang, W. (2020). Predicting coding potential of RNA sequences by solving local data imbalance. Bioinformatics 36, 4316–4322. doi: 10.1093/bioinformatics/btaa501

AUTHOR CONTRIBUTIONS

X-GC conceived the algorithm, performed the experiments, analyzed the data, and drafted the manuscript. WZ designed the experiments and revised the manuscript. XY, CL, and HC provided suggestions for the study design and the writing of the manuscript. All authors approved the final manuscript.

FUNDING

This work was funded by the National Natural Science Foundation of China (62072206, 61772381, 61976227, and 31870771), the National Science Foundation of Hubei (2020CFA025), the “Fundamental Research Funds for the Central Universities”, South-Central University for Nationalities (Grant Number CZY20039), and Huazhong Agricultural University Scientific & Technological Self-innovation Foundation.

Doja, M. N., Kaur, I., and Ahmad, T. (2020). Current state of the art for survival prediction in cancer using data mining techniques. Curr. Bioinform. 15, 174–186. doi: 10.2174/1574893614666190902152142
Fan, R. E., Chang, K. W., Hsieh, C. J., Wang, X. R., and Lin, C. J. (2008). LIBLINEAR: a library for large linear classification. JMLR 9, 1871–1874.
Fu, G. H., Wu, Y. J., Zong, M. J., and Pan, J. (2020). Hellinger distance-based stable sparse feature selection for high-dimensional class-imbalanced data. BMC Bioinform. 21:121. doi: 10.1186/s12859-020-3411-3
Gao, Y., Xiu, G., Wu, Q., and Liu, Q. (2020). Data imbalance in CRISPR off-target prediction. Brief Bioinform. 21, 1448–1454. doi: 10.1093/bib/bbaa669
Ge, L., Liu, J., Zhang, Y., and Dehmer, M. (2019). Identifying anticancer peptides by using a generalized chaos game representation. J. Math. Biol. 78, 441–463. doi: 10.1007/s00285-018-1279-x
Ge, R., Feng, G., Jing, X., Zhang, R., Wang, P., and Wu, Q. (2020). EnACP: an ensemble learning model for identification of anticancer peptides. Front. Genet. 11:760. doi: 10.3389/fgene.2020.00760
Geurts, P., Ernst, D., and Wehenkel, L. (2006). Extremely randomized trees. Machine Learn. 63, 3–42. doi: 10.1007/s10994-006-6226-1
Hajisharifi, Z., Pirayeie, M., Mohammad Beigi, M., Behbahani, M., and Mohabatkar, H. (2014). Predicting anticancer peptides with Chou’s pseudo amino acid composition and investigating their mutagenicity via Ames test. J. Theor. Biol. 341, 34–40. doi: 10.1016/j.jtbi.2013.08.037
Han, C., Xie, Q., and Lin, S. (2020). Are dropout imputation methods for scRNA-seq effective for scHi-C data? Brief Bioinform. doi: 10.1093/bib/bbaa289 [Epub ahead of print].
Hasan, M. A. M., Ben Islam, M. K., Rahman, J., and Ahmad, S. (2020). Citrullination site prediction by incorporating sequence coupled effects into PseAAC and resolving data imbalance issue. Curr. Bioinform. 15, 235–245. doi: 10.2174/1574893614666191202152328
Hoholkan, C., Van Schaeybroeck, S., Longley, D. B., and Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726. doi: 10.1038/nrc3599
Huang, F., Yue, X., Xiong, Z., Yu, Z., Liu, S., and Zhang, W. (2020). Tensor decomposition with relational constraints for predicting multiple types of microRNA-disease associations. Brief Bioinform. 22:bbaa140. doi: 10.1093/bib/bbaa140
Kawashima, S., Pokarowski, P., Pokarowska, M., Kolinski, A., Katayama, T., and Kanehisa, M. (2008). AAnxIndex: amino acid index database, progress report 2008. Nucleic Acids Res. 36, D202–D205. doi: 10.1093/nar/gkm998
Li, F. M., and Wang, X. Q. (2020). Identifying anticancer peptides by using a generalized chaos game representation. J. Math. Biol. 78, 441–463. doi: 10.1007/s00285-018-1279-x
Mahmud, S. M. H., Chen, W., Liu, Y., Awal, M. A., Ahmed, K., Rahman, M. H., et al. (2021). PreDTIs: prediction of drug-target interactions based on multiple improved hybrid compositions. Nucleic Acids Res. 49, 6202–6205. doi: 10.1093/nar/gkaa1140
Makishima, S., Koga, M., Koga, K., Nakamura, M., and Kaneko, Y. (2018). AAnxIndex: amino acid index database, progress report 2008. Nucleic Acids Res. 36, D202–D205. doi: 10.1093/nar/gkm998
Li, F. M., and Wang, X. Q. (2016). Identifying anticancer peptides by using improved hybrid compositions. Sci. Rep. 6:33910. doi: 10.1038/srep33910
Mehmood, S. M. H., Chen, W., Liu, Y., Awal, M. A., Ahmed, K., Rahman, M. H., et al. (2021). PreDTIs: prediction of drug-target interactions based on multiple feature information using gradient boosting framework with data balancing and
feature selection techniques. Brief Bioinform. doi: 10.1093/bib/bbab046 [Epub ahead of print].

Meng, C., Wei, L., and Zou, Q. (2019). SecProMTB: support vector machine–based classifier for secretory proteins using imbalanced data sets applied to Mycobacterium tuberculosis. Proteomics 19:e1900007. doi: 10.1002/pmic.201900007

Mitchell, E. P. (2006). Gastrointestinal toxicity of chemotherapeutic agents. Semin. Oncol. 33, 106–120. doi: 10.1053/j.seminoncol.2005.12.001

Naseer, S., Hussain, W., Khan, Y. D., and Rasool, N. (2020). Sequence-based identification of arginine amidation sites in proteins using deep representations of proteins and PseAAC. Curr. Bioinform. 15, 937–948. doi: 10.2174/15749361156662001191001540

Otvos, L. Jr. (2008). Peptide-based drug design: here and now. Methods Mol. Biol. 494, 1–8. doi: 10.1007/978-1-59745-419-3_1

Peng, H., Long, F., and Ding, C. (2005). Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans. Pattern Anal. Mach. Intell. 27, 1226–1238. doi: 10.1109/TPAMI.2005.159

Rumelhart, D. E., Hinton, G. E., and Williams, R. J. (1986). Learning representations by back propagating errors. Nature 323, 533–536. doi: 10.1038/323533a0

Tung, C. W., and Ho, S. Y. (2008). Computational identification of ubiquitylation sites from protein sequences. BMC Bioinform. 9:310. doi: 10.1186/1471-2105-9-310

Tyagi, A., Kapoor, P., Kumar, R., Chaudhary, K., Gautam, A., and Raghava, G. P. (2013). In silico models for designing and discovering novel anticancer peptides. Sci. Rep. 3:2984. doi: 10.1038/srep02984

Wan, S., Duan, Y., and Zou, Q. (2017). HPSLPred: an ensemble multi-label classifier for human protein subcellular location prediction with imbalanced source. Proteomics 17:1700262. doi: 10.1002/pmic.201700262

Wang, Y., Huang, G., Song, S., Pan, X., Xia, Y., and Wu, C. (2021). Regularizing deep networks with semantic data augmentation. IEEE Trans. Pattern Anal. Mach. Intell. doi: 10.1109/TPAMI.2021.3052951 [Epub ahead of print].

Wei, L., Zhou, C., Chen, H., Song, J., and Su, R. (2018). ACPred-FL: a sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides. Bioinformatics 34, 4007–4016. doi: 10.1093/bioinformatics/bty451

Wijdeven, R. H., Pang, B., Assaraf, Y. G., and Neefjes, J. (2016). Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics. Drug Resist. Updat. 28, 65–81. doi: 10.1016/j.drup.2016.07.001

Xu, L., Liang, G., Wang, L., and Liao, C. (2018). A novel hybrid sequence-based model for identifying anticancer peptides. Genes (Basel) 9:158. doi: 10.3390/genes9030158

Yu, H. C., You, Z. H., Zhou, X., Cheng, L., Li, X., Jiang, T. H., et al. (2019). ACP-DL: a deep learning long short-term memory model to predict anticancer peptides using high-efficiency feature representation. Mol. Ther. Nucleic Acids 17, 1–9. doi: 10.1016/j.omtn.2019.04.025

You, Z.-H., Zhou, M. C., Luo, X., and Li, S. (2016). Highly efficient framework for predicting interactions between proteins. IEEE Trans. Cybernet. 47, 731–743. doi: 10.1109/tcyb.2016.2524994

Yu, L., Jing, R., Liu, F., Luo, J., and Li, Y. (2020). DeepACP: a novel computational approach for accurate identification of anticancer peptides by deep learning algorithm. Mol. Ther. Nucleic Acids 22, 862–870. doi: 10.1016/j.omtn.2020.10.005

Zhang, J., and Liu, B. (2019). A review on the recent developments of sequence-based protein feature extraction methods. Curr. Bioinform. 14, 190–199. doi: 10.2174/1574936116666181212102749

Zhang, L., He, Y., Song, H., Wang, X., Lu, N., Sun, L., et al. (2020). Elastic net regularized softmax regression methods for multi-subtype classification in cancer. Curr. Bioinform. 15, 212–224. doi: 10.1016/j.cubio.2019.07.001

Zhang, W., Li, Z., Guo, W., Yang, W., and Huang, F. (2019). A fast linear neighborhood similarity-based network link inference method to predict microRNA-disease associations. IEEE/ACM Trans. Comput. Biol. Bioinform. 18, 405–415. doi: 10.1109/TCBB.2019.2931546

Zhang, Y. P., and Zou, Q. (2020). PPTPP: a novel therapeutic peptide prediction method using physicochemical property encoding and adaptive feature representation learning. Bioinformatics 36, 3982–3987. doi: 10.1093/bioinformatics/btaa273

Zhao, T., Hu, Y., and Zang, T. (2020). DRACP: a novel method for identification of anticancer peptides. BMC Bioinform. 21(Suppl. 16):559. doi: 10.1186/s12859-020-03812-y

Zou, Q. (2019). Latest machine learning techniques for biomedicine and bioinformatics. Curr. Bioinform. 14, 176–177.

Zou, Q., Ku, K., Luo, Y., Yin, D., Ju, Y., and Tang, H. (2018). Predicting diabetes mellitus with machine learning techniques. Front. Genet. 9:515.

Zou, Q., Xie, S., Lin, Z., Wu, M., and Ju, Y. (2016). Finding the best classification threshold in imbalanced classification. Big Data Res. 5, 2–8. doi: 10.1016/j.bdr.2015.12.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Zhang, Yang, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.